Remission Status at Transplantation and Treatment History Determine the Survival Chances of Patients after Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia Who Had Received Pre-Treatment with Idelalisib: A Report from the EBMT Chronic Malignancies Working Party

BACKGROUND:Numbers of patients with high-risk Chronic Lymphocytic Leukemia (CLL) who have failed Ibrutinib, Idelalisib or Venetoclax when they are referred for allogeneic hematopoietic stem cell transplantation (alloHCT) are increasing. No data is available on patients with CLL who were referred for alloHCT and were on Idelalisib prior to the start of the conditioning regimen. Therefore, we retrospectively analyzed registry data on patients with CLL who had been exposed to idelalisib prior to alloHCT.